DPP4 inhibitors reduce mortality risk in COVID-19 patients with diabetes: Study
Diabetes is one of the most significant chronic diseases that increases the severity of COVID-19 and the associated risk of mortality in the pandemic. Dipeptidyl peptidase-4 inhibitors (DPP-4is) are a class of medications that are used due to their anti-inflammatory, anti-fibrotic, and anti-adipogenic properties.
A new study by Rifat Emral and team revealed that there is an association between DDP-4is use and reduced mortality in people with Type 2 Diabetes Mellitus( T2DM) who were tested positive for COVID-19. Further Less frequent intensive care unit admission and/or mechanical ventilation were also observed among patients using DPP-4 inhibitors.
The findings of the study are published in Diabetes Therapy.
The objective of the study was to investigate the effect of pre existing treatment with DPP-4i on COVID-19-related hospitalization and mortality in patients with type T2DM.
The study was a multicenter, retrospective cohort study conducted using patient data extracted from the Turkish National Electronic Database. All patients who tested positive for COVID-19 (PCR test) between 11 March through to 30 May 2020 were screened for eligibility (n = 149,671). Following exclusion of patients based on pre-determined inclusion criteria, patients with T2DM using a DPP-4i or glucose-lowering medications other than a DPP-4i were compared for mortality and hospitalization. The propensity score method was used to match age, gender, micro- and macrovascular complications, and medications in the two groups. Independent associates of mortality were analyzed using multivariable analysis on the whole T2DM population.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.